Theravance Biopharma/TBPH

$9.10

-3.6%
-
1D1W1MYTD1YMAX

About Theravance Biopharma

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath and others. Its pipeline of internally discovered programs is targeted to address unmet patient needs. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. Its Selective 5-HT4 Agonist (TD-8954) is a selective 5-HT4 receptor agonist, which is developed for the treatment of gastrointestinal motility disorders.

Ticker

TBPH

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Rick Winningham

Employees

111

Headquarters

George town, Cayman Islands

TBPH Metrics

BasicAdvanced
$470.09M
Market cap
-
P/E ratio
-$0.97
EPS
0.37
Beta
-
Dividend rate

What the Analysts think about TBPH

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
51.1% upside
High $20.00
Low $10.00
$9.10
Current price
$13.75
Average price target

TBPH Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-48.57% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$17.5M
12.18%
Net income
$-8.5M
-4.49%
Profit margin
-48.57%
-14.86%

TBPH Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 14.35%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.35
-$0.28
-$0.17
-$0.17
-
Expected
-$0.26
-$0.21
-$0.21
-$0.15
-$0.18
Surprise
34.74%
33.33%
-18.92%
14.35%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Theravance Biopharma stock

Buy or sell Theravance Biopharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing